163 related articles for article (PubMed ID: 28920711)
1. Rivaroxaban Causes Missed Diagnosis of Protein S Deficiency but Not of Activated Protein C Resistance (Factor V Leiden).
Maryamchik E; Rosenbaum MW; Van Cott EM
Arch Pathol Lab Med; 2018 Jan; 142(1):70-74. PubMed ID: 28920711
[TBL] [Abstract][Full Text] [Related]
2. Apixaban Does Not Interfere With Protein S or Activated Protein C Resistance (Factor V Leiden) Testing Using aPTT-Based Methods.
Maryamchik E; Van Cott EM
Arch Pathol Lab Med; 2020 Nov; 144(11):1401-1407. PubMed ID: 32101451
[TBL] [Abstract][Full Text] [Related]
3. Lack of rivaroxaban influence on a prothrombinase-based assay for the detection of activated C protein resistance: an Italian ex vivo and in vitro study in normal subjects and factor V Leiden carriers.
Gessoni G; Valverde S; Valle L; Gessoni F; Caruso P; Valle R
Int J Lab Hematol; 2017 Aug; 39(4):418-422. PubMed ID: 28318106
[TBL] [Abstract][Full Text] [Related]
4. Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American Specialized Coagulation Laboratories.
Smock KJ; Plumhoff EA; Meijer P; Hsu P; Zantek ND; Heikal NM; Van Cott EM
Thromb Haemost; 2016 Jul; 116(1):50-7. PubMed ID: 27075008
[TBL] [Abstract][Full Text] [Related]
5. The effect of dabigatran and rivarovaban on a prothrombinase-based assay for activated protein C resistance: a preliminary study in subjects heterozygous for factor V Leiden.
Gessoni G; Valverde S; Gessoni F; Valle R
Blood Transfus; 2015 Oct; 13(4):666-8. PubMed ID: 25761318
[No Abstract] [Full Text] [Related]
6. A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations.
Favaloro EJ; Orsag I; Bukuya M; McDonald D
Pathology; 2002 Aug; 34(4):348-55. PubMed ID: 12190294
[TBL] [Abstract][Full Text] [Related]
7. Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference.
Favaloro EJ; Gilmore G; Bonar R; Dean E; Arunachalam S; Mohammed S; Baker R
Clin Chem Lab Med; 2020 Jul; 58(8):1322-1331. PubMed ID: 32126010
[TBL] [Abstract][Full Text] [Related]
8. Danger of false negative (exclusion) or false positive (diagnosis) for 'congenital thrombophilia' in the age of anticoagulants.
Favaloro EJ
Clin Chem Lab Med; 2019 May; 57(6):873-882. PubMed ID: 30485173
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Gessoni G; Valverde S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
[TBL] [Abstract][Full Text] [Related]
10. The predictability of factor V Leiden (FV:Q(506)) gene mutation via clotting-based diagnosis of activated protein C resistance.
Sayinalp N; Haznedaroğlu IC; Aksu S; Büyükaşik Y; Göker H; Parlak H; Ozcebe OI; Kirazli S; Dündar SV; Gürgey A
Clin Appl Thromb Hemost; 2004 Jul; 10(3):265-70. PubMed ID: 15247984
[TBL] [Abstract][Full Text] [Related]
11. APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant women.
Sedano-Balbás S; Lyons M; Cleary B; Murray M; Gaffney G; Maher M
BMC Pregnancy Childbirth; 2010 Mar; 10():11. PubMed ID: 20214832
[TBL] [Abstract][Full Text] [Related]
12. New functional assays to selectively quantify the activated protein C- and tissue factor pathway inhibitor-cofactor activities of protein S in plasma.
Alshaikh NA; Rosing J; Thomassen MCLGD; Castoldi E; Simioni P; Hackeng TM
J Thromb Haemost; 2017 May; 15(5):950-960. PubMed ID: 28211163
[TBL] [Abstract][Full Text] [Related]
13. Activated protein C resistance -- in the absence of factor V Leiden -- and pregnancy.
Lindqvist PG; Svensson P; Dahlbäck B
J Thromb Haemost; 2006 Feb; 4(2):361-6. PubMed ID: 16420566
[TBL] [Abstract][Full Text] [Related]
14. An improved algorithm for activated protein C resistance and factor V Leiden screening.
Herskovits AZ; Morgan EA; Lemire SJ; Lindeman NI; Dorfman DM
Am J Clin Pathol; 2013 Sep; 140(3):379-86. PubMed ID: 23955457
[TBL] [Abstract][Full Text] [Related]
15. The impact of oral anticoagulant therapy, factor VIII level and quality of factor V-deficient plasma on three commercial methods for activated protein C resistance.
Chitolie A; Lawrie AS; Mackie IJ; Harrison P; Machin SJ
Blood Coagul Fibrinolysis; 2001 Apr; 12(3):179-86. PubMed ID: 11414631
[TBL] [Abstract][Full Text] [Related]
16. Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non-carriers of the factor V Leiden mutation.
Guerrero F; Arnaud C; Nguyen F; Boneu B; Sié P
Thromb Haemost; 2006 Apr; 95(4):728-34. PubMed ID: 16601846
[TBL] [Abstract][Full Text] [Related]
17. [Diagnosis of thrombophilia]].
Kemkes-Matthes B
Zentralbl Chir; 2001 Jun; 126(6):433-7. PubMed ID: 11446062
[TBL] [Abstract][Full Text] [Related]
18. Activated protein C resistance in young African American patients with ischemic stroke.
Chaturvedi S; Joshi N; Dzieczkowski J
J Neurol Sci; 1999 Mar; 163(2):137-9. PubMed ID: 10371074
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Testing Approaches for Activated Protein C Resistance and Factor V Leiden: A Comparison of Institutional and National Provider Practices.
Perez Botero J; Majerus JA; Strege AK; Johnson RD; Chen D; Pruthi RK
Am J Clin Pathol; 2017 Jun; 147(6):604-610. PubMed ID: 28472350
[TBL] [Abstract][Full Text] [Related]
20. The response to activated protein C after cardiopulmonary bypass: impact of factor V leiden.
Donahue BS
Anesth Analg; 2004 Dec; 99(6):1598-1603. PubMed ID: 15562039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
